Stock Analysis
- United Kingdom
- /
- Healthtech
- /
- AIM:COG
Cambridge Cognition Holdings Full Year 2023 Earnings: In Line With Expectations
Cambridge Cognition Holdings (LON:COG) Full Year 2023 Results
Key Financial Results
- Revenue: UK£13.5m (up 7.2% from FY 2022).
- Net loss: UK£3.51m (loss widened by UK£3.10m from FY 2022).
- UK£0.10 loss per share (further deteriorated from UK£0.013 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Cambridge Cognition Holdings Meets Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.
Looking ahead, revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare Services industry in Europe.
Performance of the market in the United Kingdom.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
Before you take the next step you should know about the 1 warning sign for Cambridge Cognition Holdings that we have uncovered.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:COG
Cambridge Cognition Holdings
A neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally.